We are live on ! Find out more
ALBO

Albireo Pharma Inc

Delisted

ALBO was delisted on the 2nd of March, 2023.

41 hedge funds and large institutions have $32.9M invested in Albireo Pharma Inc in 2013 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more call options, than puts

Call options by funds: $2.84M | Put options by funds: $1.05M

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

2% less funds holding

Funds holding: 4241 (-1)

31% less capital invested

Capital invested by funds: $47.8M → $32.9M (-$14.9M)

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
41
Holders Change
-1
Holders Change %
-2.38%
% of All Funds
1.33%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
11
Increased
13
Reduced
7
Closed
11
Calls
$2.84M
Puts
$1.05M
Net Calls
+$1.79M
Net Calls Change
+$1.49M
Name Holding Trade Value Shares
Change
Change in
Stake
AWMDMG
1
Austin W. Marxe & David M. Greenhouse
New York
$4.99M +$2.06M +15,810 +43%
GPP
2
Great Point Partners
Connecticut
$4.2M +$5.79M +44,483 New
VM
3
VHCP Management
New York
$4.04M -$715K -5,494 -11%
William Blair & Company
4
William Blair & Company
Illinois
$3.27M
BC
5
Broadfin Capital
New York
$3.15M +$2.34M +18,007 +117%
O
6
OrbiMed
New York
$2.83M -$7.78M -59,763 -67%
NI
7
Numeric Investors
Massachusetts
$2.02M +$2.78M +21,382 New
Wellington Management Group
8
Wellington Management Group
Massachusetts
$1.75M
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.24M +$45.8K +352 +3%
Goldman Sachs
10
Goldman Sachs
New York
$1.22M -$434K -3,331 -21%
AG
11
Artal Group
Luxembourg
$916K
FNYS
12
First New York Securities
New York
$772K +$1.06M +8,167 New
Millennium Management
13
Millennium Management
New York
$454K +$626K +4,805 New
TC
14
TFS Capital
Pennsylvania
$390K +$421K +3,234 +361%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$245K +$166K +1,272 +97%
DY
16
Dowling & Yahnke
California
$202K +$43.4K +333 +18%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$176K -$5.08K -39 -2%
CS
18
Credit Suisse
Switzerland
$144K +$199K +1,529 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$140K +$68.6K +527 +55%
BFA
20
BlackRock Fund Advisors
California
$136K +$14.7K +113 +9%
Group One Trading
21
Group One Trading
Illinois
$132K -$70K -538 -28%
California Public Employees Retirement System
22
California Public Employees Retirement System
California
$71K
OC
23
Oppenheimer & Co
New York
$63K +$86.8K +667 New
Citadel Advisors
24
Citadel Advisors
Florida
$58K -$24.2K -186 -23%
SKK
25
Shepherd Kaplan Krochuk
Massachusetts
$56K -$17.3K -133 -18%

ALBO Hedge Fund Activity: Q3 2013 in Review

41 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q3 2013, worth a combined $32.9M — down 31% from $47.8M a quarter earlier.

Fund positioning in ALBO was balanced in Q3 2013: 11 funds opened new positions, 11 closed out, 13 added to existing stakes and 7 trimmed.

The largest buyer was Numeric Investors, opening a new position worth an estimated $2.78M. The largest seller was OrbiMed, cutting an estimated $7.78M.

  • 41 institutional investors held Albireo Pharma Inc (ALBO) as of Q3 2013, down from 42 in Q2 2013.
  • Funds reported $32.9M of Albireo Pharma Inc stock for Q3 2013, down 31% quarter-over-quarter.
  • 11 funds opened new Albireo Pharma Inc positions in Q3 2013 and 11 closed out, a net change of 0 holders.
  • The largest Albireo Pharma Inc buyer in Q3 2013 was Numeric Investors, an estimated $2.78M added.
  • The largest Albireo Pharma Inc seller in Q3 2013 was OrbiMed, an estimated $7.78M sold.

Based on aggregated 13F filings for Q3 2013.